C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
Increased capability to produce medicines for challenging diseases including cancer
SigTuple’s AI100 with Shonit is the premier solution for AI assisted digital pathology
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
Subscribe To Our Newsletter & Stay Updated
